Skip to main content
BDTX logo

Black Diamond Therapeutics, Inc.

BDTXNASDAQHealthcareBiotechnology

$1.69Today:- (-)1Y −46.39%

As of Oct 26, 2026 close

Market cap
$96.95M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.60$4.94
Volume (live)
-
Avg. volume (3M)
810.67K

Black Diamond Therapeutics (BDTX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Black Diamond Therapeutics generated $29.61M of operating cash flow. Free cash flow was $29.61M, or 42.3% of revenue.

Black Diamond Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Black Diamond Therapeutics, Inc. (BDTX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income22.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93-4.60
Depreciation & Amortization0.330.34-0.740.512.390.050.050.040.02
Deferred Income Tax0.000.000.000.002.181.730.000.000.41
Stock Based Compensation6.6310.639.6012.2014.047.773.640.060.01
Change in Working Capital-8.73-2.693.69-9.907.025.040.460.351.74
Change in Accounts Payable-3.431.680.60-2.231.571.071.450.26-0.06
Change in Other Working Capital-5.302.97-0.852.73-3.263.97-0.990.091.80
Other Operating Activities9.022.973.172.732.000.526.430.020.07
Net Cash from Operating Activities29.61-62.30-66.72-85.08-100.15-52.15-24.67-8.45-2.35
Investing Activities
Capital Expenditures0.000.00-0.03-0.19-2.71-0.14-0.02-0.08-0.08
Acquisitions0.030.090.000.012.700.120.000.000.00
Purchases of Investments-164.03-122.88-61.89-60.14-49.51-372.480.000.000.00
Sales/Maturities of Investments119.02139.7578.17113.69182.8390.930.000.000.00
Other Investing Activities0.070.000.100.00-2.70-0.120.000.000.00
Net Cash from Investing Activities-44.9116.9716.3553.37130.61-281.69-0.02-0.08-0.08
Financing Activities
Debt Repayment0.000.000.000.000.000.000.000.00-0.05
Common Stock Issued-0.1524.4971.930.180.73213.840.0052.310.10
Other Financing Activities0.001.050.080.000.001.10127.7652.3119.95
Net Cash from Financing Activities-0.1525.5571.930.180.73214.94127.7652.319.97
Summary
Net Change in Cash-15.44-19.7921.56-31.5431.19-118.89103.0643.787.55
Cash at Beginning of Period37.2657.0435.4867.0235.83154.7251.667.880.33
Cash at End of Period21.8237.2657.0435.4867.0235.83154.7251.667.88
Free Cash Flow29.61-62.30-66.75-85.27-102.86-52.29-24.70-8.53-2.43

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Black Diamond Therapeutics Cash Flow

What is Black Diamond Therapeutics's free cash flow?

Black Diamond Therapeutics generated free cash flow of $29.61M in fiscal 2025 (fiscal year ended Dec 31, 2025). Free cash flow equaled 42.3% of revenue.

Does Black Diamond Therapeutics pay dividends or buy back shares?

Black Diamond Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition